Protagonist Therapeutics announced the nomination of PN-477 as a development candidate for obesity, a novel triple agonist peptide targeting GLP-1, GIP, and Glucagon receptors. This strategic move marks the company's entry into the rapidly growing metabolic disease market.
PN-477 is designed to offer an optimal combination of total body weight loss, improved gastrointestinal tolerability, and a favorable fat-to-lean mass ratio. The company plans to develop both an oral formulation (PN-477o) for once-daily dosing and a subcutaneous version (PN-477sc) for once-weekly administration.
IND-enabling studies for PN-477 are progressing, with Phase 1 clinical studies anticipated to begin in the second quarter of 2026. This expansion leverages Protagonist's proprietary peptide engineering platform to address a significant unmet medical need with a differentiated therapeutic approach.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.